31483-56-4Relevant academic research and scientific papers
Preparation of 2,5-disubstituted pyrimidines from vinamidinium salts and synthesis of novel disulfane derivatives
Rafiee Samani, Ziba,Mehranpour, Abdolmohammad,Hasaninejad, Alireza
supporting information, p. 2150 - 2156 (2020/03/10)
Novel pyrimidine derivatives were prepared from the reaction of 2-substituted 1,3-bis(dimethylamino)-trimethinium salts with thiourea or guanidine in the presence of ethyl-diisopropylamine in ethanol at reflux, and also some 5-substituted pyrimidine-2-thi
Nitrogen-containing heterocyclic organic compounds and organic electroluminescent device (by machine translation)
-
Paragraph 0100-0104, (2019/11/04)
The invention relates to a nitrogen-containing heterocyclic organic compounds and organic electroluminescent device, the nitrogen containing heterocyclic organic compound of the following general structure (I) shown: Wherein X is N or CH; Y is a single bo
HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS
-
Page/Page column 212, (2009/01/23)
Disclosed are the ERK inhibitors of formula 1.0: [Formula (1.0)] and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS
-
Page/Page column 237-238, (2008/06/13)
Disclosed are the ERK inhibitors of formula 1.0 and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
PYRROLIDINE DERIVATIVES AS ERK INHIBITORS
-
Page/Page column 184, (2010/11/28)
Disclosed are the ERK inhibitors of Formula (1.0): and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of Formula (1.0).
